US EditionPublished • loading... • Updated
Novo Nordisk partners with Vivtex in up to $2.1 billion deal for oral ...
Novo Nordisk’s $2.1 billion deal with Vivtex aims to develop oral biologic pills for obesity and diabetes, expanding access beyond injectable drugs, with 50,000 weekly prescriptions reported.
- On Wednesday, Novo Nordisk signed a $2.1 billion deal with Boston startup Vivtex to develop oral drug-delivery technologies for obesity and metabolic diseases, including upfront payments and royalties.
- Amid pipeline setbacks and rival advances, Novo Nordisk launched an oral Wegovy pill a few weeks ago and aims to develop oral biologics due to poor gastrointestinal absorption of injectables.
- Vivtex's platform uses smartphone-sized `gut-on-a-chip` devices and combines robotics-driven screening with AI to test thousands of formulations; founded in 2018 by MIT researchers Robert Langer, Giovanni Traverso, and Thomas von Erlach, it has multiple pharma partnerships.
- Vivtex will receive an undisclosed guaranteed upfront payment and could gain up to $2.1 billion, as well as royalties, if candidates are commercialized, intensifying competition with Lilly.
- Analysts estimate the GLP‑1 market will reach $150 billion by 2030 as oral formulations like Wegovy gain rapid uptake with nearly 250,000 prescriptions last month and about 50,000 weekly.
Insights by Ground AI
17 Articles
17 Articles
Stock Market Today, Feb. 25: Novo Nordisk Dips After Announcing $2.1 Billion Partnership With Vivtex for Oral Drug-Delivery Technologies
Novo Nordisk (NYSE:NVO), which develops and markets diabetes and obesity treatments, closed Wednesday at $38.16, down 1.11%. The stock slipped as investors weighed a large Vivtex partnership while watching how competition and margins shape Novo’s obesity and diabetes franchise. Trading volume reached 54.7 million shares, about 141% above its three-month average of 22.7 million shares. Novo Nordisk IPO'd in 1981 and has grown 23,750% since going …
·Alexandria, United States
Read Full Article
Companies claim that collaboration aims to develop biological medicines for next generation for obesity, diabetes and diseases associated with oral formulations
·Brazil
Read Full Article
Coverage Details
Total News Sources17
Leaning Left3Leaning Right2Center6Last UpdatedBias Distribution55% Center
Bias Distribution
- 55% of the sources are Center
55% Center
L 27%
C 55%
R 18%
Factuality
To view factuality data please Upgrade to Premium
